

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

FAIRHURST ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/003516

FILED: 2 APRIL 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: QUINOLINE-2-ONE DERIVATIVES FOR THE TREATMENT OF  
AIRWAYS DISEASES

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/003516, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Gregory C. Houghton  
Attorney for Applicants  
Reg. No. 47,666

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614

Date: 10/3/05

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
PR/4-83-560  
APPLICATION NO.  
Not Yet Known  
APPLICANT  
FAIRHURST ET AL.  
FILING DATE  
Herewith10/552023  
Sheet 1 of 2  
Rec'd PCT/PTC 03 OCT 2005

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,460,581	7/17/84	Fuegner et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	0 073 505	3/9/83	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	93/18007	9/16/93	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	00/75114	12/14/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	02/45703	6/13/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Patent Abstracts of Japan, Vol. 0010, No. 45 (C-011) (1977) and JP 52 000282, January 5, 1977 -- Abstract.
AS	Patent Abstracts of Japan, Vol. 0062, No. 61 (C-141) (1982) and JP 57 154129, September 22, 1982 - Abstract.
AT	Patent Abstracts of Japan, Vol. 0082, No. 5 (C-243) (1984) and JP 59 093051, May 29, 1984 -- Abstract.
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
PR/4-10-11  
APPLICATION NO.  
Not Yet Known  
APPLICANT  
FAIRHURST ET AL.  
FILING DATE  
Herewith

Sheet 2 of 2

10/552023  
10-10 Rec'd PCT/PTC 03 OCT 2005

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BA	Patent Abstracts of Japan, Vol. 0082, No. 5 (C-243) (1984) and JP 59 093052, May 29, 1984 -- Abstract.
BB	Patent Abstracts of Japan, Vol. 0092, No. 71 (C-311) (1985) and JP 60 120864, June 28, 1985 -- Abstract.
BC	Yoshizaki et al., "Sympathomimetic Amines Having a Carbostyryl Nucleus", J. Med. Chem., Vol. 19, No. 9, pp. 1138-1142 (1976).
BD	
BE	
BF	
BG	
BH	
BI	
BJ	
BK	
BL	
BM	
BN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.